More Videos
SPECIAL REPORT
MOST SHARED
- Jobless Claims Post Another Drop as Picture Improves
- Obama Plans Jobs Summit But Not Second Stimulus
- Meet The Leaders of the New Retail Revolution
- Wal-Mart Holiday Forecast Light, Profit Beats
- A Public Hearing That Isn't Public
- "Friending" Big Pharma
- Obama Most Powerful Person in World: Forbes
- 30 Year Mortgage Rate Falls Again; Lowest In Five Weeks
- Activision Says 'Call of Duty' Sets Launch Record
- Big Bounce Coming — Play These 6 Stocks: Chief Investor
- Wal-Mart Looks Even Better Next Quarter: Strategist
- Fourteen Stocks that Could Gain from Dollar's Decline
- Busch: Another Obama Opportunity
- Light the Lights! Buffett and Gates Prepare to Answer Students' Questions at Columbia
- Farrell: Retailers?
- A Public Hearing That Isn't Public
- Boise State's Brilliant Stock Plan
- Apple's Global Retail Invasion
- US Debating What to Do With Billions of TARP Money Left
- For Video Game Makers, Stakes Are High for Holidays
- In Charity Tax Filing, a Real Glimpse of Goldman Sachs
- Obama Begins Asia Trip, Burdened by Jobs, Economy
- FHA Reserves Fall Below Required Level: HUD Chief
- 30-Year Mortgage Rate Falls Again; Lowest in Five Weeks
- Ford, Hyundai, Audi Gaining Consumer Interest
- US Mortgage Refinancing Up; Buying Demand Sinks
- Intel Agrees to Pay AMD $1.25 Billion to Settle Disputes
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
Researchers looked at all sorts of cardiovascular medications including cholesterol fighters, also known as statins. The top-selling statin--the top-selling drug in the world, for that matter--is Lipitor from Pfizer [PFE
Loading...
()
]. The pill rakes in around $13 billion a year, but sales growth has stalled since Zocor from Merck [MRK
Loading...
()
]went generic and companies, doctors and insurers started putting more patients on the cheaper alternative. The new JAMA study, which included clinical trials of generic Zocor, could presumably spur that trend.
PhRMA the drug industry's main lobbying organization, put out a statement late yesterday on the JAMA study saying, "The contention that brand-name medicines drive up the cost of health care is fatally flawed. Without today's innovative brand-name drugs to legally copy, there would be no generic drug industry. Worse yet, there would be little hope of finding new treatments and cures for a wide range of debilitating--and often deadly--diseases."
You expect a group like PhRMA to take a defensive position. That's its job. But I was surprised when this press release from Pfizer popped up in the inbox this morning (see link below) only hours after the JAMA study came out.
The communication touts the results of another study being published in "Mayo Clinic Proceedings" showing that Lipitor works 13 percent better than generic Zocor in preventing heart attacks, stroke, etc. The senior VP of Pfizer's global medical division, Dr. Michael Berelowitz, is quoted as saying, "The latest analysis adds to the wealth of real-world data from a number of different medical database analyses that suggest that patients who are treated with Lipitor may have a reduced risk of experiencing a cardiovascular event compared with patients who use simvastatin."
Simvastatin is the scientific, generic name for Zocor. And to drive home the point, the Dr. Berelowitz statement finishes with, "Findings such as these should be taken into account by those who may assume that medicines in a therapeutic class are interchangeable and provide similar outcomes."
That's an interesting opinion to be voiced so close on the heels of a much more prominent JAMA study that draws the exact opposite conclusion.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes